Sepsis management - Antibiotic therapy;Antibiotikatherapie der sepsis

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 48, 2004, Pages 2609-2613

  Welte, T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; DRUG EFFICACY; ENTEROBACTERIACEAE; ENTEROCOCCUS; EPIDEMIOLOGICAL DATA; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; PNEUMONIA; PROGNOSIS; REVIEW; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS; TREATMENT INDICATION;

ANTI-BACTERIAL AGENTS; HUMANS; INTENSIVE CARE; SEPSIS;

EID: 9944258089     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-836084     Document Type: Review

References (38)

1. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809
2. Anderson S. Linezolid: a review of its use in the management of seroius gram-positive infections. Drugs 2001; 61: 525-551
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated cost of care. Crit Care Med 2001; 29: 1303-1310
4. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS, Andremont A, Chiou CC International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440-444
5. Bernard GR, Vincent JL, Laterre PF. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
6. Bodmann KF, Vogel F. Antimikrobielle Therapie der Sepsis. Chemotherapie Journal 2001; 10: 43-55
7. Brun-Boisson C, Roudot-Thoraval F, Girou E, Grennier-Sennelier E, Durand-Saleski I. The cost of sepsissyndromes in the intensive care unit and influence of hospital acquired sepsis. Intensive Care Med 2003; 29: 1464-1471
8. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47: 2756-2764
9. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator- associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 2588-2598
10. Cosgrove SE, Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 53-59
11. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banachloche J, Keh D, Marshall JC, Parker MM, Ramsey Gzimmermann JL, Vincent JL, Levy MM. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-555
12. Ewig S, Dalhoff K, Lorenz J, Mauch H, Schaberg T, Ukena D, Weite T, Wilkens H, Witt C. Empfehlungen zur Diagnostik der nosokomialen Pneumonie. Pneumologie 1999; 53: 499-510
13. Gang RK, Sanyal SC, Mokkaddas E, Lari AR. Rifampicin as an adjunct to vancomycin therapy in MRSA septicaemia in burns. Burns 1999; 25: 640-644
14. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742-2751
15. Geddes A, Thaler M, Schonwald S, Harkonen M, Jacobs F, Nowotny I. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. J Antimicrob Chemother 1999; 44: 799-810
16. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119: 1114-1122
17. Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001; 48: 209-217
18. Gruson D, Hilbert G, Vargas F, Valentino R, Bui N, Pereyre S, Bebear C, Bebear CM, Gbikpi-Benissan G. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003; 31: 1908-1914
19. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29: 1109-1115
20. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.Chest 2002; 122: 262-268
21. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-394
22. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474
23. Kollmar O, Schilling MK. Chirurgische Konzepte zur Therapie der schweren Sepsis. Anaesthesist 2003; 52: S15-15(Suppl 1
24. MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004; 38: 284-288
25. Malacarne P, Rossi C, Bertolini G. Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study. J Antimicrob Chemother 2004; 54: 221-224
26. Mandell LA, Bartlett JG, Dowell SF, Jr. File TM, Musher DM, Whitney C Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433
27. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, GarbinoJ, Calandra T, Glauser MP, Tauber MG, Pittet D Fungal Infection Network of Switzerland. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-320
28. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554
29. Moerer O, Schmid A, Hofmann M, Herklotz A, Reinhart K, Werdan K, Schneider H, Burchardi H. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 2002; 28: 1440-1446
30. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-888
31. Osmon S, Warren D, Seiler SM, Shannon W, Fraser VJ, Kollef MH. The influence of infection on hospital mortality for patients requiring>48h of intensive care. Chest 2003; 124: 1021-1029
32. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140: 26-32
33. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Brit Med J 2004; 328: 668
34. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519-527
35. Thomas C, Stevenson M, Williamson DJ, Riley TV. Clostridium difficile-associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis 2002; 35: 1457-1462
36. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531-539
37. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123: 1615-1624
38. www.cdc.gov/ncidod/hip/NNIS/members/2001NNIS_report.pdf,